Abstract Library

#3449 Cavum neuroendocrine carcinoma

Introduction: Small cell neuroendocrine carcinoma of the head and neck is an unusual entity, especially in the cavum, given their rarity and the lack of randomized trials. The therapeutic management of these tumors is difficult. Their prognosis remains unfavourable.

Conference:

Presenting Author:

Authors: Aris H, Ghomari S,

Keywords: Small cell neuroendocrine carcinoma, Cavum,

#3366 Long-term stabilization in a patient with neuroendocrine carcinoma of the laryngopharynx after systemic treatment

Introduction: A clinical case of a patient with neuroendocrine cancer of the laryngopharynx with an initially aggressive course is presented.

Conference:

Presenting Author:

Authors: Androsova A, Orlova R, Ivanova A, Belyak N, Kutukova S,

Keywords: neuroendocrine cancer, laryngeal cancer, chemotherapy,

#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma

Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Martin C, Mitrache M, Nitipir C, Terzea D, Stroescu C,

Keywords: pulmonary neuroendocrine tumors, pituitary macroadenoma,

#2266 Prognostic Value of the Different Pre-Treatment Biomarkers for Patients with Neuroendocrine Tumors

Introduction: Several inflammatory response materials could be used for prediction of prognosis in cancer patients. The neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), thrombocytosis (the platelets number >400*103/mm3) have been introduced for prognostic scoring system in various cancers.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: croitoru A

Authors: Grigorescu R, Croitoru A, Stanel I, Gheorghe C, Grama I,

Keywords: prognostic factors, survival,

#2243 Somatostatin Analogs (SSAs) as Effective Treatment of Resectable, non Metastatic, non Functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Patients Unfit for Surgery. A Case Series.

Introduction: SSAs are used to treat symptomatic functioning pNETs and to prolong progression free survival in metastatic, G1/G2, somatostatin receptor-positive pNETs. Pancreatic surgery is burdened with important morbidity and mortality, especially in patients with increased anaesthesiological risk.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Nessi C, Paiella S, Miotto M, Viviani E, Zingaretti C,

Keywords: somatostatin analogs, resectable pnets,